La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Gyre Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Gyre Therapeutics..

Gyre Therapeutics (NASDAQ:GYRE) Azioni, Quote.MetaTitle.option-chain

Gyre Therapeutics

Panoramica

Notizie

Utili

Opzioni

Guidance

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Comments

Gyre Therapeutics Catena di Opzioni

Opzioni

Gyre Therapeutics (NASDAQ:GYRE) Azioni, Quote.MetaTitle.option-chain

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO